1. Introduction

The Artificial Endocrine Accountability Doctrine can be understood as a proposed legal and governance framework for ensuring accountability when artificial technologies interact with, monitor, simulate, or regulate the human endocrine system.

The endocrine system consists of glands and tissues that produce hormones, including the thyroid, pituitary, adrenal glands, pancreas, ovaries, and testes. Hormones influence growth, metabolism, reproduction, stress responses, and other essential bodily functions.

Technologies that may raise these legal questions include:

Artificial-pancreas systems and automated insulin delivery.

AI-based hormone monitoring and endocrine diagnostic tools.

Digital systems used to recommend hormone replacement or fertility treatments.

Implantable devices that release hormones or other therapeutic substances.

Artificial intelligence used in pharmaceutical development and endocrine research.

Biotechnologies that modify hormone production or endocrine function.

Important legal clarification: As of October 2026, “Artificial Endocrine Accountability Doctrine” is not a universally recognized, standalone legal doctrine established by a leading court. It is best treated as a proposed analytical framework constructed from existing principles of medical negligence, product liability, informed consent, data protection, administrative accountability, and biotechnology regulation.

Its central objective is to ensure that every organization or professional involved in developing, approving, supplying, or using an artificial endocrine technology can be held accountable for unlawful conduct, preventable harm, or regulatory failure.

2. Meaning and essential principles

The proposed doctrine can be organized around six principles.

1. Safety accountability

Manufacturers and developers should assess foreseeable risks, validate system performance, and provide appropriate safeguards against dangerous errors.

2. Informed consent and bodily autonomy

Patients should receive understandable information about treatment risks, alternatives, uncertainties, and the role of automated decision-making.

3. Clinical accountability

Healthcare professionals and institutions must exercise appropriate clinical judgment rather than blindly relying on an algorithm or device.

4. Data accountability

Sensitive hormone, fertility, genetic, and reproductive information must be collected and processed lawfully and securely.

5. Fairness and non-discrimination

Decisions should not unlawfully discriminate based on sex, disability, age, reproductive status, or other legally protected characteristics.

6. Transparency and remedies

Patients and regulators should have access to appropriate explanations, incident records, complaint mechanisms, and legal remedies.

These principles do not automatically create independent legal duties. Their enforceability depends on the legislation, regulations, professional standards, and facts applicable to a particular case.

3. Important case laws and their relevance

Although no reported judgment appears to establish this exact doctrine, several landmark decisions provide a strong legal foundation for applying accountability principles to artificial endocrine technologies.

Case 1: Samira Kohli v. Dr. Prabha Manchanda (2008)

Supreme Court of India · (2008) 2 SCC 1

Facts: A patient consented to diagnostic laparoscopy but underwent additional surgery involving removal of her uterus, ovaries, and fallopian tubes while under anaesthesia. Her mother had consented to the additional surgery, but the patient herself was a competent adult.

Legal issue: Could a doctor perform a substantially different procedure without the competent adult patient's consent?

Decision and principle: The Supreme Court emphasized the patient's right to bodily autonomy and held that consent for one procedure does not generally authorize a materially different procedure. An additional procedure without consent may be justified in a genuine emergency where delaying treatment would be unreasonable and necessary to preserve life or health.

Indian Kanoon

+1

Application to artificial endocrine governance: Suppose an AI-assisted endocrine treatment system recommends hormone therapy, but a clinician or provider introduces a materially different intervention without obtaining appropriate consent. The principles in Samira Kohli would be relevant to whether that intervention was authorized.

The case also highlights the importance of explaining material risks, alternatives, and the nature of treatment before using technologies that affect reproductive or hormonal functions.

Case 2: Jacob Mathew v. State of Punjab (2005)

Supreme Court of India · (2005) 6 SCC 1

Legal principle: The judgment discusses medical negligence and the standard of care expected from medical professionals. It distinguishes an adverse medical outcome from legally culpable negligence and addresses the threshold for criminal liability.

Application: If a doctor relies on an artificial-pancreas system or an AI-based hormone recommendation, the legal question would include whether the doctor acted with the degree of skill and care reasonably expected in the circumstances.

A software error does not automatically establish criminal negligence by the doctor. The evidence must support the applicable legal elements. Separate questions may arise about a manufacturer's defective design, inadequate warnings, or a hospital's failure to maintain equipment.

Case 3: Indian Medical Association v. V.P. Shantha (1995)

Supreme Court of India · (1995) 6 SCC 651

Legal principle: The Supreme Court addressed when medical services fall within consumer-protection law, including the treatment of services supplied for consideration and the position of certain free medical services.

Application: Where an endocrine technology is supplied as part of paid clinical services, a patient may be able to pursue an appropriate consumer-protection remedy if the statutory requirements are met.

Potential issues include:

An AI diagnostic system that repeatedly misclassifies hormone disorders.

A hospital's failure to maintain an automated insulin-delivery device.

Deficient clinical services involving an implantable drug-delivery system.

The availability of a consumer remedy depends on the applicable law, the nature of the service, and the facts of the dispute.

Case 4: V. Kishan Rao v. Nikhil Super Speciality Hospital (2010)

Supreme Court of India · (2010) 5 SCC 513

Legal principle: The Court considered the use of expert evidence in medical-negligence cases and rejected the idea that expert opinion is invariably required in every such case.

Application: In a dispute concerning an artificial endocrine device, evidence could include device logs, clinical records, algorithm validation studies, expert endocrinology testimony, and engineering assessments.

The case supports a fact-sensitive approach to proof. The technical complexity of an AI system should not, by itself, prevent a patient from seeking a legal remedy.

Case 5: K.S. Puttaswamy v. Union of India (2017)

Supreme Court of India · (2017) 10 SCC 1

Legal principle: The Supreme Court recognized privacy as a fundamental right under Article 21 and the constitutional framework.

Application: Artificial endocrine systems may process particularly intimate information, including menstrual-cycle patterns, fertility indicators, hormone measurements, pregnancy-related information, and reproductive-health predictions.

The constitutional privacy framework is relevant to state action and may inform the protection of sensitive medical information more broadly. Its precise application depends on the circumstances and applicable statutory law.

For example, an organization should not assume that a patient's use of a hormone-monitoring application automatically authorizes unrelated commercial profiling or disclosure of reproductive-health information.

Case 6: Schoendorff v. Society of New York Hospital (1914)

United States · 211 N.Y. 125

Legal principle: This influential decision articulated the principle that a competent adult has a right to determine what is done to their body.

Application: It provides comparative-law support for bodily autonomy in technologies that deliver hormones, alter endocrine function, or make treatment decisions. It is not binding precedent in India, but its underlying principle is consistent with the reasoning in Samira Kohli.

Case 7: Montgomery v. Lanarkshire Health Board (2015)

United Kingdom Supreme Court · [2015] UKSC 11

Legal principle: The Court emphasized a doctor's duty to take reasonable care to ensure that patients are aware of material risks and reasonable alternatives to proposed treatment.

Application: If an artificial endocrine intervention carries a material risk of hypoglycaemia, hormonal imbalance, fertility effects, or another significant adverse outcome, the disclosure obligations must be assessed under the applicable jurisdiction's law.

The decision is especially useful for comparative analysis of patient-centred consent. It does not establish a universal disclosure rule for every jurisdiction.

Case 8: Montgomery v. Lanarkshire Health Board (2015)

United Kingdom Supreme Court · [2015] UKSC 11

Legal principle: Patients must be informed of material risks and reasonable alternatives to proposed treatment.

Application: A patient considering a new hormone-delivery implant should receive adequate information about material risks, alternatives, and relevant uncertainties. This case provides persuasive comparative guidance, rather than binding Indian law.

Case 9: World Health Organization guidance on AI in healthcare (2021)

This is not a judicial precedent, but it is an important governance source.

The WHO's Ethics and Governance of Artificial Intelligence for Health emphasizes human rights, transparency, safety, accountability, and appropriate oversight throughout the development and use of healthcare AI.

World Health Organization

+1

Its recommendations support a governance model in which AI systems assist healthcare professionals without eliminating responsibility for clinical decisions or system failures.

4. Statutory and regulatory framework in India

The proposed doctrine would operate through existing laws and regulatory mechanisms rather than as an independent cause of action.

India's Central Drugs Standard Control Organisation (CDSCO) regulates medical devices through the applicable statutory framework. Government information published in March 2026 specifically addresses the regulatory pathway for AI-enabled medical devices and technical documentation under the Medical Devices Rules, 2017.

Press Information Bureau

+1

The precise classification of a product depends on its intended use and applicable rules. An ordinary wellness application, a diagnostic algorithm, an automated insulin-delivery device, and an implantable drug-delivery system should not automatically be treated as legally identical.

5. Governance and allocation of responsibility

An effective accountability framework should identify the responsible actor at every stage.

Stage 1 — Research and development

Responsible actors: Researchers, developers, manufacturers, and research institutions.

Governance duties: Validate safety and performance, document limitations, investigate foreseeable risks, and comply with research ethics requirements.

Stage 2 — Regulatory approval

Responsible actors: Manufacturers, applicants, and competent regulatory authorities.

Governance duties: Supply accurate technical documentation, substantiate safety and performance claims, and meet the relevant authorization requirements.

Stage 3 — Clinical deployment

Responsible actors: Hospitals, clinicians, laboratories, and device operators.

Governance duties: Obtain valid consent, assess patient suitability, maintain devices, monitor treatment, and retain appropriate records.

Stage 4 — Post-market monitoring

Responsible actors: Manufacturers, healthcare providers, and regulators.

Governance duties: Report relevant adverse events, investigate malfunctions, implement corrective action, and communicate safety information as legally required.

Stage 5 — Complaints and remedies

Responsible actors: Courts, consumer commissions, regulators, and other competent bodies.

Governance duties: Preserve evidence, determine causation and responsibility, provide legally available remedies, and enforce applicable standards.

The WHO's guidance supports oversight throughout the AI lifecycle, including careful selection, deployment, monitoring, and maintenance of clinical technologies. It also recognizes that responsibility may arise at multiple levels, including healthcare professionals, hospitals, and technology developers.

Iris

+1

6. Illustrative legal scenarios

Scenario A: Automated insulin delivery failure

An artificial-pancreas system delivers an excessive insulin dose because of a foreseeable software defect, causing severe hypoglycaemia.

Potential legal questions include:

Was the device defective or inadequately tested?

Were warnings and safety instructions adequate?

Did the hospital or user follow appropriate procedures?

Was the defect a legally relevant cause of the injury?

Which statutory or civil remedies are available?

Depending on the evidence, responsibility could arise under product liability, negligence, or applicable medical-device law. Liability is not automatic merely because an adverse event occurred.

Scenario B: AI misdiagnoses a thyroid disorder

An AI system repeatedly classifies abnormal thyroid results as normal, delaying treatment.

A court may need to consider the quality of the software, its intended use, the clinician's review obligations, the hospital's procurement and deployment practices, and whether the delay caused compensable harm.

The reasoning in Jacob Mathew and V. Kishan Rao may assist with questions concerning professional negligence and proof.

Scenario C: Unauthorized hormonal intervention

A competent adult is given a substantially different hormone treatment from the one authorized, without a genuine emergency.

The principles in Samira Kohli are directly relevant to the consent issue. The legality of the treatment, the evidence of harm, and the available remedies would need to be assessed separately.

Scenario D: Misuse of reproductive-health data

An endocrine application discloses identifiable fertility or hormone data to an unrelated commercial organization without an adequate legal basis.

The privacy principles in Puttaswamy may be relevant to constitutional questions, particularly where state action is involved. Statutory data-protection obligations and their applicability must also be examined.

7. Evidentiary standards and accountability challenges

Artificial endocrine technologies may create difficult evidentiary questions because treatment outcomes depend on biological variability, device design, clinical judgment, and environmental factors.

A claimant may need to establish:

Duty: The defendant owed a legally recognized duty.

Breach: The applicable standard was not met.

Causation: The breach caused or materially contributed to the legally relevant harm under the applicable test.

Damage: The claimant suffered a legally recognized injury or loss.

Remedy: The relevant law authorizes compensation, corrective action, or another form of relief.

Useful evidence may include medical records, hormone test results, device logs, software versions, maintenance histories, clinical guidelines, validation reports, and expert opinions.

A key reform proposal would be to require appropriate audit trails and incident-reporting systems for high-risk endocrine technologies. Such measures could improve the ability of patients, courts, and regulators to reconstruct decisions and identify failures.

However, a proposed reform must be distinguished from an existing legal duty: whether a specific audit trail, disclosure, or reporting requirement is mandatory depends on the applicable rules.

8. Critical evaluation

The proposed Artificial Endocrine Accountability Doctrine offers a useful way to organize the legal problems created by increasingly automated and technologically complex endocrine care.

Its principal strengths are:

Clearer allocation of responsibility: Separating the duties of developers, manufacturers, clinicians, and institutions.

Protection of bodily autonomy: Preserving informed consent when technology influences treatment.

Better evidence preservation: Encouraging records sufficient to investigate device and algorithm failures.

Privacy protection: Recognizing the sensitive nature of endocrine and reproductive information.

Lifecycle governance: Extending safety oversight beyond initial approval to deployment and monitoring.

Its limitations are equally important. The doctrine has no universally settled elements, and it cannot independently establish liability, reverse evidentiary burdens, or create compensation rights without an applicable legal basis. Existing laws may also allocate responsibility differently across jurisdictions.

9. Conclusion

The Artificial Endocrine Accountability Doctrine and Governance Framework is best understood as a proposed interdisciplinary legal model for governing artificial technologies that influence hormonal and endocrine functions.

In India, its strongest legal foundations include Samira Kohli on informed consent, Jacob Mathew on medical negligence, Indian Medical Association v. V.P. Shantha on consumer protection in medical services, V. Kishan Rao on evidence in medical-negligence disputes, and K.S. Puttaswamy on constitutional privacy. These authorities address related legal principles; none establishes the named doctrine itself.

The central governance objective is to ensure that technological innovation does not remove responsibility from the people and institutions that design, approve, supply, and use endocrine technologies. Accountability must remain grounded in demonstrable legal duties, reliable evidence, patient autonomy, and effective remedies.

This is a general academic legal analysis, not a determination of liability in a specific case.